Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: ENHERTU Supplemental New Drug Application submitted in Japan as adjuvant therapy for patients with HER2 positive early breast cancer Daiichi Sankyo has taken a new step to […]
Weekly Digest – March 2026 Weekly Digest – March 2026 03 March 2026: ABL Bio–NEOK Bio receive U.S. IND clearance for phase 1 clinical trial of ABL209 (NEOK002) ABL Bio and NEOK Bio have advanced their next-generation ADC pipeline after […]
Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: PADCEV + Keytruda cuts risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive bladder cancer Pfizer and Astellas Pharma reported strong Phase 3 results for […]
Weekly Digest – March 2026 Weekly Digest – March 2026 28 February 2026: Henlius doses first patient in phase 2/3 trial of anti-HER2 mAb HLX22 in combination with anti-HER2 ADC HLX87 for first-line treatment of HER2-positive breast cancer Shanghai Henlius […]
Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: WuXi XDC enters strategic collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform WuXi XDC has announced a strategic collaboration with Earendil Labs to advance next-generation antibody-drug […]
Weekly Digest – March 2026 Weekly Digest – March 2026 27 February 2026: Ligachem Bio and Ono Pharmaceutical accelerate joint ADC research, receiving follow-up milestones Ligachem Biosciences has announced that it will receive additional development milestone payments from Ono Pharmaceutical […]
